Dendritic Cell Vaccination for Patients with Solid Tumors

Inclusion Criteria: 1. Tumor type: Metastatic or Locally Advanced Breast Cancer; Malignant Mesothelioma; Glioblastoma Multiforme (Grade IV); Sarcoma's; Colorectal tumors or rare tumors (less than 500 patients a year) 2. Extent of disease: * Metastatic Breast Cancer or High Risk Locally Advanced Breast Cancer * Partial or Complete response after first line chemotherapy for both metastatic or locally advanced breast cancer. Minimal metastatic disease under hormonal treatment * High risk Locally Advanced breast cancer defined as (and/or): * Age \< 60 years old * ER, PR and Her-2 Neu negative tumors * \> 4 lymphnodes at initial presentation * Mastitis Carcinomatosis * Pregnancy associated Breast Cancer * Malignant Mesothelioma: * Partial or Complete response after first line chemotherapy not amendable for surgery * Adjuvant after debulking surgery * Glioblastoma Multiforme * In Recurrent Disease after optimal treatment according to Stupp regimen * In primary disease after debulking surgery, Temodal/radiotherapy and Temodal chemotherapy for 6 months * Sarcoma's * After adjuvant chemotherapy for uterine sarcoma's * After Optimal or Debulking Surgery for liposarcoma's, synovial cell sarcoma's * Recurrent sarcoma's with limited disease * Colorectal tumors * K-ras wild-type tumors with inoperable lymphnode metastasis after standard chemotherapy (FOLFOX, FOLFIRI) 3. Patient Characteristics * Prior treatments: Patients must have received at least one prior chemotherapeutic regimen and must be more than 1 month past the last treatment. * Age: ≥ 18 years old * Performance status: WHO PS grade 0-1 (Appendix B) * Objectively assessable parameters of life expectancy: more than 3 months * Prior and concomitant associated diseases allowed with the exception of underlying autoimmune disease and positive serology for HIV/HBV/HCV * No concomitant use of immunosuppressive drugs, hormonal treatment for breast cancer is allowed in case of stable disease * Adequate renal and liver function, i.e. creatinin and bilirubin = 1.2 times the upper limit of normal * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial * Women of child-bearing potential should use adequate contraception prior to study entry and for the duration of study participation Exclusion Criteria: 1. Subjects with concurrent additional malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix) 2. Subjects who are pregnant 3. Subjects who have sensitivity to drugs that provide local anesthesia 4. Subjects needing corticosteroids 1 mg/kg during vaccination; corticosteroids are allowed as part of their treatment when taken ≥ 30 days before the start of vaccination.